Global Insight Services have recently published a report on Dry Eye Syndrome – Drug Pipeline Landscape, 2022. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Dry eye syndrome (DES) is a condition that occurs when the eyes do not produce enough tears, or when the tears are of poor quality. This can lead to symptoms such as burning, itching, redness, and a feeling of grittiness or sandiness in the eyes. DES is a very common condition, affecting up to 30% of the population. It is more common in women than men, and the risk increases with age.
Dry eye syndrome ( keratoconjunctivitis sicca) is a chronic progressive condition due to lack of moisture and lubrication, resulting in constant irritation of the surface of the eye.
Request Sample Report : https://www.globalinsightservices.com/request-sample/GIS31011
Report Highlights
Global Insight Service’s, Dry Eye Syndrome – Drug Pipeline Landscape, 2022 report provides an overview of the Dry Eye Syndrome pipeline drugs. This report covers detailed insights on Dry Eye Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Dry Eye Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Key Players
• Abbvie
• Abilita Bio Inc
• Aerie Pharmaceuticals
• Aldeyra Therapeutics, Inc.
• Allegro Ophthalmics LLC
• Allgenesis Biotherapeutics Inc
• Allysta Pharmaceutical
• Aramis Biosciences, Inc.
• AstraZeneca
• Aviara Pharmaceuticals Inc
• Avixgen Inc
• AxeroVision, Inc
• Azura Ophthalmics
• BRIM Biotechnology Inc
Inquire Before Buying : https://www.globalinsightservices.com/inquiry-before-buying/GIS31011
With Global Insight Services, you receive:
• 10-year forecast to help you make strategic decisions
• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Excel data pack included with all report purchases
• Robust and transparent research methodology
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/